[go: up one dir, main page]

SK10742003A3 - Vodná kompozícia amfotericínu B - Google Patents

Vodná kompozícia amfotericínu B Download PDF

Info

Publication number
SK10742003A3
SK10742003A3 SK1074-2003A SK10742003A SK10742003A3 SK 10742003 A3 SK10742003 A3 SK 10742003A3 SK 10742003 A SK10742003 A SK 10742003A SK 10742003 A3 SK10742003 A3 SK 10742003A3
Authority
SK
Slovakia
Prior art keywords
amphotericin
sodium chloride
phospholipids
composition
micronized
Prior art date
Application number
SK1074-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Srikanth Pai
Sangeeta Rivankar
Original Assignee
Bharat Serums & Vaccines Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd. filed Critical Bharat Serums & Vaccines Ltd.
Publication of SK10742003A3 publication Critical patent/SK10742003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SK1074-2003A 2001-03-01 2001-03-16 Vodná kompozícia amfotericínu B SK10742003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN217MU2001 IN188924B (fr) 2001-03-01 2001-03-01
PCT/IN2001/000040 WO2002069983A1 (fr) 2001-03-01 2001-03-16 Composition aqueuse d'amphoterocine b

Publications (1)

Publication Number Publication Date
SK10742003A3 true SK10742003A3 (sk) 2004-01-08

Family

ID=11097223

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1074-2003A SK10742003A3 (sk) 2001-03-01 2001-03-16 Vodná kompozícia amfotericínu B

Country Status (23)

Country Link
US (1) US20040137049A1 (fr)
EP (1) EP1368041B1 (fr)
JP (1) JP2004523566A (fr)
KR (1) KR100810067B1 (fr)
CN (1) CN1255114C (fr)
AT (1) ATE274913T1 (fr)
AU (1) AU2001250643B2 (fr)
BG (1) BG108188A (fr)
BR (1) BR0116922A (fr)
CA (1) CA2438847A1 (fr)
CZ (1) CZ20032264A3 (fr)
DE (1) DE60105322T2 (fr)
DK (1) DK1368041T3 (fr)
EA (1) EA006241B1 (fr)
ES (1) ES2227172T3 (fr)
IN (1) IN188924B (fr)
MX (1) MXPA03007777A (fr)
NZ (1) NZ528281A (fr)
PT (1) PT1368041E (fr)
SK (1) SK10742003A3 (fr)
WO (1) WO2002069983A1 (fr)
YU (1) YU75403A (fr)
ZA (1) ZA200307307B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006069929A (ja) * 2004-08-31 2006-03-16 Konica Minolta Medical & Graphic Inc 真菌症治療製剤およびその製造方法
EA200700440A1 (ru) * 2004-09-13 2008-02-28 Бхарат Сирумс Энд Вэксинс Лтд. Композиции стабильных эмульсий для внутривенного введения, имеющие защитную эффективность
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8052996B2 (en) 2005-02-03 2011-11-08 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
CN100418536C (zh) * 2005-04-06 2008-09-17 河南省眼科研究所 一种用于眼科的抗真菌药物组合物
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
CA2726861C (fr) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
KR101629521B1 (ko) * 2010-03-16 2016-06-13 우석대학교 산학협력단 난용성 약물 가용화 및 생체막 투과증진을 위한 알코올성 수상을 내상으로 하는 리포좀, 리포좀 조성물 및 리포좀의 제조방법
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102525921B (zh) * 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
US9744191B2 (en) 2012-03-19 2017-08-29 Yale University Antimicrobial compositions and methods
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
EP3222324B1 (fr) * 2016-03-23 2020-05-13 Wayne State University Valproate en tant que traitement antifongique topique
CA3024479A1 (fr) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Polypeptides selectifs du recepteur du glucagon et methodes pour les employer
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
CN108344811A (zh) * 2017-01-24 2018-07-31 北京泰德制药股份有限公司 一种注射用脂质体中有机溶剂残留的检测方法
CN108309955B (zh) * 2018-04-27 2020-06-02 武昌理工学院 一种聚明胶肽结合型紫杉醇纳米颗粒的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
JP3956402B2 (ja) * 1996-03-04 2007-08-08 日本油脂株式会社 アンホテリシンｂ運搬体
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use

Also Published As

Publication number Publication date
BR0116922A (pt) 2004-04-27
CZ20032264A3 (cs) 2003-12-17
CA2438847A1 (fr) 2002-09-12
NZ528281A (en) 2006-11-30
ES2227172T3 (es) 2005-04-01
KR100810067B1 (ko) 2008-03-05
EP1368041B1 (fr) 2004-09-01
DK1368041T3 (da) 2005-01-17
EA006241B1 (ru) 2005-10-27
IN188924B (fr) 2002-11-23
EP1368041A1 (fr) 2003-12-10
EA200300948A1 (ru) 2004-04-29
AU2001250643B2 (en) 2007-03-22
ZA200307307B (en) 2004-04-20
CN1505519A (zh) 2004-06-16
BG108188A (bg) 2004-09-30
YU75403A (sh) 2006-05-25
PT1368041E (pt) 2005-01-31
CN1255114C (zh) 2006-05-10
MXPA03007777A (es) 2003-12-08
WO2002069983A1 (fr) 2002-09-12
KR20040018337A (ko) 2004-03-03
DE60105322T2 (de) 2005-09-15
US20040137049A1 (en) 2004-07-15
JP2004523566A (ja) 2004-08-05
ATE274913T1 (de) 2004-09-15
DE60105322D1 (de) 2004-10-07

Similar Documents

Publication Publication Date Title
SK10742003A3 (sk) Vodná kompozícia amfotericínu B
AU2002312777B2 (en) Method and composition for solubilising a biologically active compound with low water solubility
AU2001250643A1 (en) Amphotericin B aqueous composition
EP1682116B1 (fr) Procede de preparation de particules sous-microniques de paclitaxel ou docetaxel
AU2002312777A1 (en) Method and composition for solubilising a biologically active compound with low water solubility
CN102018714B (zh) 制剂
JPH11507369A (ja) プレリポソーム凍結乾燥体から得られるサブミクロンリポソーム懸濁液
RU2391966C1 (ru) Наносистема на основе растительных фосфолипидов для включения биологически активных соединений и способ ее получения (варианты)
JP2798302B2 (ja) リポソームおよび脂質複合体組成物の調製
KR20060135729A (ko) 중추신경계 전달 증가를 위한 항레트로바이러스제의나노현탁액
NO880403L (no) Parenterale suspensjoner.
AU634644B2 (en) Parenterally administrable lipsome formulation comprising synthetic lipids
MX2007007442A (es) Modificadores de superficie de (polialcoxi)sulfonato.
US20090011001A1 (en) Manufacturing process for liposomal preparations
US5720973A (en) Preparation of colloidal aqueous solutions of active substances of low solubility and a lipid therefor
CN100431525C (zh) 脂质体悬浮液制造方法及含该法所制脂质体悬浮液的产物
CN119486716A (zh) 新型度格列汀制剂及其制备方法
CN1795867A (zh) 多柔比星脂质体及其制备方法和用途
UA64591A (en) Method for producing lyposomal composition of anticancer antibiotic
MXPA06008533A (en) Nanosuspensions of anti-retroviral agents for increased central nervous system delivery